Samsung C&T and Samsung Electronics will invest $110 million in GRAIL at $70.05/share to commercialize the Galleri multi-cancer early detection test in South Korea; definitive agreements expected in early 2026 with possible expansion to Japan and Singapore.Read More
$110M investment brings GRAIL’s Galleri to Asia — Samsung to commercialize in South Korea with possible Japan & Singapore expansion
By Stock Titan
